We are live on ! Find out more
CRL icon

Charles River Laboratories

407 hedge funds and large institutions have $5.16B invested in Charles River Laboratories in 2018 Q4 according to their latest regulatory filings, with 77 funds opening new positions, 117 increasing their positions, 155 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

215% more call options, than puts

Call options by funds: $18.3M | Put options by funds: $5.82M

141% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 32

11% more funds holding

Funds holding: 366407 (+41)

2.02% less ownership

Funds ownership: 97.11%95.09% (-2%)

18% less capital invested

Capital invested by funds: $6.27B → $5.16B (-$1.11B)

25% less repeat investments, than reductions

Existing positions increased: 117 | Existing positions reduced: 155

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
407
Holders Change
+41
Holders Change %
+11.2%
% of All Funds
9.07%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
77
Increased
117
Reduced
155
Closed
32
Calls
$18.3M
Puts
$5.82M
Net Calls
+$12.5M
Net Calls Change
+$931K
Name Holding Trade Value Shares
Change
Change in
Stake
N
251
Nuveen
North Carolina
$605K
SI
252
Shaker Investments
Ohio
$588K
WMG
253
WESCAP Management Group
California
$579K
GI
254
GAMCO Investors
Connecticut
$566K -$250K -2,000 -29%
LIM
255
Leavell Investment Management
Alabama
$543K
ProShare Advisors
256
ProShare Advisors
Maryland
$521K -$132K -1,057 -19%
SG Americas Securities
257
SG Americas Securities
New York
$518K -$412K -3,292 -42%
TAM
258
Tyers Asset Management
Texas
$514K -$136K -1,088 -19%
Grantham, Mayo, Van Otterloo & Co (GMO)
259
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$509K +$213K +1,700 +61%
AG
260
Advisor Group
Arizona
$507K -$17.4K -139 -3%
TC
261
TownSquare Capital
Utah
$505K +$500K +3,992 New
GC
262
Guggenheim Capital
Illinois
$500K -$7.45M -59,483 -93%
DCM
263
Dupont Capital Management
Delaware
$500K -$502K -4,009 -48%
GCA
264
Gideon Capital Advisors
New York
$474K +$525K +4,190 New
Marshall Wace
265
Marshall Wace
United Kingdom
$461K -$5.44M -43,432 -91%
FA
266
FDx Advisors
Illinois
$460K -$141K -1,130 -22%
Group One Trading
267
Group One Trading
Illinois
$460K +$509K +4,062 New
LPL Financial
268
LPL Financial
California
$453K -$74.4K -594 -13%
M&T Bank
269
M&T Bank
New York
$453K -$2K -16 -0.4%
Lazard Asset Management
270
Lazard Asset Management
New York
$447K +$331K +2,646 +203%
PTC
271
Private Trust Company
Ohio
$442K -$171K -1,367 -26%
SO
272
STRS Ohio
Ohio
$442K +$119K +951 +32%
MYIA
273
Mount Yale Investment Advisors
Colorado
$438K -$21.9K -175 -5%
PIA
274
Piedmont Investment Advisors
North Carolina
$422K +$159K +1,272 +52%
MML Investors Services
275
MML Investors Services
Massachusetts
$417K -$111K -886 -19%

CRL Hedge Fund Activity: Q4 2018 in Review

407 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q4 2018, worth a combined $5.16B — down 18% from $6.27B a quarter earlier.

Buyers outnumbered sellers: 77 funds opened new CRL positions and 32 closed out — a net gain of 45 holders — while 117 added to existing stakes and 155 trimmed.

The largest buyer was Epoch Investment Partners, opening a new position worth an estimated $43.1M. The largest seller was Fidelity International, cutting an estimated $96.6M.

  • 407 institutional investors held Charles River Laboratories (CRL) as of Q4 2018, up from 366 in Q3 2018.
  • Funds reported $5.16B of Charles River Laboratories stock for Q4 2018, down 18% quarter-over-quarter.
  • 77 funds opened new Charles River Laboratories positions in Q4 2018 and 32 closed out, a net change of +45 holders.
  • The largest Charles River Laboratories buyer in Q4 2018 was Epoch Investment Partners, an estimated $43.1M added.
  • The largest Charles River Laboratories seller in Q4 2018 was Fidelity International, an estimated $96.6M sold.

Based on aggregated 13F filings for Q4 2018.